NASDAQ:STAB Statera Biopharma (STAB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends Get Statera Biopharma alerts: Email Address About Statera Biopharma Stock (NASDAQ:STAB) 30 days 90 days 365 days Advanced Chart Ad InvestorPlaceAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt industries worth over $46 trillion. What's even more intriguing?Click here to uncover how you can get in on the ground floor. Get Statera Biopharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume474 shsAverage Volume17,920 shsMarket Capitalization$5,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewStatera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.Read More… Are You Ready for a Small-Cap Rally? (Ad)Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt industries worth over $46 trillion. What's even more intriguing?Click here to uncover how you can get in on the ground floor. Receive STAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Statera Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address STAB Stock News HeadlinesFed-up Minnesotans warn Tim Walz uses Midwest charm to drive far-left policies: ‘He will stab you in the back’August 10, 2024 | nypost.comDog-walking NY couple turns table on would-be mugger who was hospitalized with stab wounds: videoMay 19, 2024 | foxnews.comForget Trump and KamalaForget Trump and Kamala. I don't care who you vote for - This calendar is the only thing that matters right now.September 20, 2024 | Investors Alley (Ad)Bridgend: Wife begged ex-councillor to end stab attack - courtMay 8, 2024 | bbc.co.ukStatera BioPharma Inc Ordinary SharesApril 18, 2024 | morningstar.comCRAIG D. LINDER SELECTED TO 2024 TOP 50 LAWYERS IN AMERICAApril 12, 2024 | finance.yahoo.comArrests after man found with serious stab injuriesApril 7, 2024 | bbc.comPolice appeal after man found with stab injuriesApril 4, 2024 | bbc.comSee More Headlines STAB Stock Analysis - Frequently Asked Questions How do I buy shares of Statera Biopharma? Shares of STAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today9/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STAB CUSIPN/A CIK1318641 Webwww.staterabiopharma.com Phone(888) 613-8802Fax716-849-6820Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.49 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares54,662,000Free Float51,656,000Market Cap$5,000.00 OptionableNot Optionable Beta0.42 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:STAB) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
